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ABSTRACT 
Atypical haemolytic uraemic syndrome is caused 
by alternative complement pathway dysregulation. 
It has recently been recognised that most cases are 
due to genetic factors and a growing list of muta-
tions has been described. Atypical haemolytic uraemic 
syndrome is associated with a dismal prognosis, a 
relapsing course, high acute mortality and frequent 
progression to end-stage renal disease.
We describe a five-year-old boy admitted with a 
first recurrence of atypical haemolytic uraemic syn-
drome. The primary onset of the disease was at 15 
months of age, following which there was complete 
recovery of haematological and renal parameters. His 
family history was significant in that his mother had 
died at the age of only 23 years of a stroke with 
associated thrombotic microangiopathy, suggesting 
a familial form of the disease. Sequencing of the 
gene encoding complement factor H revealed a 
heterozygous SCR20 mutation (3644G>T, Arg1215Leu), 
confirming the diagnosis. The patient was successfully 
treated with fresh frozen plasma infusions that 
induced disease remission.
We also review currently evolving concepts about 
atypical haemolytic uraemic syndrome caused by 
factor H mutation, its diagnosis, the role of genetic 
testing and management strategies in children.
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INTRODUCTION 
Haemolytic uraemic syndrome (HUS) is part of a 
group of thrombotic microangiopathies affecting mul-
tiple organ systems, but predominantly the kidney. 
It is defined by a clinical triad of microangiopathic 
haemolytic anaemia, thrombocytopaenia and acute 
renal injury, induced by the formation of platelet 
thrombi in the microcirculation of the kidney1. 
Although rare, it is the most common cause of acute 
renal failure in young children.
HUS is classically divided into typical or atypical 
(aHUS) subtypes, based on clinical presentation and 
the association with bacteria that produce shiga-like 
toxin (Stx), frequently Escherichia coli of the O157:H7 
serotype. Typical (or Stx associated) HUS is the most 
common form in children, accounting for 90% of all 
cases. It usually occurs after a prodromal episode of 
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bloody diarrhoea (D+), has a self-limiting course and 
relatively good prognosis, with complete recovery of 
renal function.
On the other hand, atypical HUS (the non-Stx 
related form) can occur from infancy to adulthood, 
is responsible for only 10% of cases in children and 
is not associated with a diarrhoeal prodrome (D-). 
Although the clinical presentation of aHUS can be 
variable, it usually carries a poor prognosis, with a 
relapsing course, high acute mortality (25%), frequent 
progression to end-stage renal disease (ESRD) (50%) 
and recurrence of the syndrome after kidney trans-
plant (30-100%)1-5.
It is now recognised that up to 60% of aHUS is 
associated with mutations in genes encoding alterna-
tive complement pathway components and their 
regulators, leading to excessive complement activa-
tion and consequent endothelial damage. Some 
genetic mutations have been identified including: i) 
‘loss of function’ mutations in genes encoding com-
plement regulatory proteins which normally protect 
host cells from complement activation [factor H (CFH), 
factor I (CFI); complement factor H-related proteins 
(CFHR) and membrane cofactor protein (MCP or 
CD46)], ii) ‘gain of function’ mutations in the genes 
encoding the complement activators [complement 
factor B (CFB) and C3], iii) mutations in thrombo-
modulin (THBD), and iv) functional factor H deficiency 
due to anti-CFH auto antibodies6.
The latest advances in understanding the pathogen-
esis of aHUS have led to a revised classification of the 
syndrome. As a result, according to Noris M. et al.6, 
aHUS can be categorised as genetic, acquired or idio-
pathic. Genetic aHUS can also be classified as multiplex 
(i.e. familial with two or more affected family members) 
or simplex (i.e. a single occurrence in a family)6. Familial 
aHUS occurs in less than 20% of cases and has poor 
prognosis, with a rate of either ESRD or death of 50 
to 80%. Both autosomal dominant and recessive pat-
terns of inheritance have been reported7.
In this article we report a rare paediatric case of 
genetic, familial aHUS, caused by factor H mutation, 
with a recurrent clinical course. Currently evolving 
concepts about aHUS will be discussed, with a special 
focus on diagnostic strategies, the role of genetic 
testing and new management strategies for children 
with aHUS.
CASE REPORT 
A five-year-old boy was admitted to our paediatric 
nephrology unit with the diagnosis of a first recur-
rence of aHUS. Disease onset was at 15 months of 
age, when he had been admitted with a two-week 
history of weakness, pallor, loss of appetite, and 
lethargy. At that time, there was no history of fever, 
diarrhoea, vomiting, respiratory or urinary symptoms 
and no other signs of disease were noted. There 
was no exposure to sick contacts. He had no previ-
ous serious illnesses, took no medications, and had 
received all immunisations. His parents were not 
consanguineous, but his family history was significant 
in that his mother had died at the age of only 23 
years of a stroke and thrombotic microangiopathy. 
Physical examination revealed no significant abnor-
mality, except pallor. Laboratory evaluation demon-
strated anaemia [haemoglobin (Hgb) 5.6 g/dL], normal 
white blood cell count (WBC) (8.6x103cells/dL), mild 
thrombocytopaenia (125x109/L), elevated reticulocyte 
count (20%) and high lactate dehydrogenase (LDH) 
(4354 IU/L; normal range: 230-460). Direct Coombs 
test was negative. A peripheral blood film showed 
fragmented red blood cells (RBC), polychromasia, 
and acanthocytes, consistent with the diagnosis of 
microangiopathic haemolytic anaemia. Investigations 
also revealed mild renal injury [elevated blood urea 
nitrogen (BUN) 9.6 mmol/L; serum creatinine (Scr) 
40μmol/L; urinalysis with mild haematuria (10-15 
RBCs/FPF) and protein/creatinine ratio 1.1 mg/mg].
A presumptive diagnosis of aHUS was made, with 
the suspicion of a familial disease. The patient was 
managed with fluid and electrolyte therapy and there 
was complete resolution of the haematological and 
renal abnormalities. Anaemia was well tolerated and 
no blood transfusion was necessary during this first 
episode.
Studies of Von Willebrand factor-cleaving protease 
activity (ADAMTS 13), including genetic analysis, were 
normal. Over the following four years he was well 
and developed normally.
At the age of five years, the child was readmitted 
with a 1-week history of jaundice, fatigue, pallor, 
lethargy and intermittent abdominal pain. Once again, 
there was no history of preceding diarrhoea, fever 
or vomiting, though he did have an upper respiratory 
tract infection treated with a course of amoxicillin 
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and clavulanate two weeks prior to admission. On 
physical examination, the child had normal vital signs 
except for high blood pressure (135/89 mmHg). 
Inspection revealed pallor, mild icterus and multiple 
scattered petechiae. He had no other rashes and no 
lymphadenopathy, abdominal tenderness or hepa-
tosplenomegaly. Neurological examination was nor-
mal. Laboratory findings were Hgb 6.7g/dL; WBC 
5.4x103cells/dL and platelet count 48x109/L. The 
peripheral blood smear showed fragmented erythro-
cytes, schizocytes, marked anisocytosis and throm-
bocytopaenia. Serum biochemistry was urea 7.9 
mmol/L; Cr 129.9 μmol/L; LDH 3522 IU/L; haptoglobin 
<0.243 g/L (0.45-2.05); and normal electrolytes. Uri-
nalysis revealed microscopic haematuria (15 RBCs/
HPF) and proteinuria (protein/creatinine ratio 2.3mg/
mg). D-dimer and direct Coombs tests were negative. 
The coagulation screen (including prothrombin time, 
activated partial thromboplastin time, fibrinogen, and 
antithrombin III levels) was normal.
This second presentation with microangiopathic 
haemolytic anaemia, thrombocytopaenia and acute 
renal injury, and on this occasion, with associated 
hypertension, was consistent with a first recurrence 
of aHUS. He was managed conservatively with fluid 
and electrolyte monitoring, blood transfusion, blood 
pressure control and nutritional advice. Fresh frozen 
plasma (FFP) infusion was started (10 ml/kg twice 
daily for the first two weeks, reduced to once a day 
in the third week). Blood pressure control was 
achieved with triple antihypertensive medication 
(nifedipine 20mg bid, enalapril 10mg bid, losartan 
25mg id). Dialysis was not required. The subsequent 
course was favourable and after 3 weeks the child 
was discharged with improved haematologic and 
renal parameters (Hgb 8.4 g/dl; platelets 229x109/L; 
Cr 44.2 μmol/L and urea 24.5mmol/L).
An extensive work-up was performed. Anti-nuclear 
antibodies, anti-double stranded DNA antibodies, 
anti-neutrophil cytoplasmic antibody, antibodies to 
extractable nuclear antigens and glomerular base-
ment membrane were all negative. Serum levels of 
immunoglobulins (G, M, A), were normal. Comple-
ment C3 was normal (154.0 mg/dl) and C4 level low 
(8.1mg/dl, 83-177). Studies of ADAMTS 13, including 
functional and genetic analysis, were again normal. 
Serum factor H and factor I levels were in the normal 
range. Genetic studies performed at Mario Negri 
Institute for Pharmacological Research (Bergamo, 
Italy), under the auspices of the International Registry 
of Recurrent and Familial HUS/TTP, disclosed a 
heterozygous mutation in factor H gene, leading to 
the amino acid substitution (Arg1210Leu) at position 
3644 (3644G>T) in short consensus report unit 20 
(SCR20) hot-spot mutation region of the terminal 
part of the CHF molecule. Investigation of other 
genetic disorders of complement regulation pre-
formed at the same institution (CD46-MCP, factor I 
and ADAMTS 13) were all negative.
After discharge, the child continued treatment with 
darbepoetin, antihypertensive drugs and FFP infu-
sions (10 ml/kg, 3 times per week for the first week 
reducing to once every 3 weeks over 6 months).
The patient is now seven years old. At last follow-
up, 20 months after the recurrence, haematological 
and renal parameters were normal and blood pres-
sure was normal without medication. There have 
been no further relapses of aHUS.
DISCUSSION 
Atypical HUS is a rare disease and remains a 
diagnostic and therapeutic challenge. A high index 
of suspicion is required for early recognition and 
appropriate treatment. Children with aHUS have a 
varied clinical presentation and course. These are 
influenced by the underlying gene mutation, which 
is also significant in predicting response to treatment 
and outcome8.
Our patient had an initial presumptive diagnosis 
of aHUS based on clinical presentation, laboratory 
findings and familial background. Sequencing of the 
gene CFH encoding complement factor H revealed a 
heterozygous SCR20 mutation [(3644G>T, resulting 
in the exchange of arginine by leucine at position 
1215 (Arg1215Leu)] that confirmed the diagnosis. 
Mutations at the same position of CFH sequence 
have already been described in other patients affect-
ed by aHUS and the presence of a SCR20 mutation 
of factor H is a strong predisposing factor for the 
disease9.
Mutations in gene encoding for factor H are the 
most common cause of aHUS (30%). Patients are 
generally heterozygous and the disease presents 
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early in childhood in approximately 70% of affected 
individuals. Children with aHUS caused by CFH gene 
mutation usually have the worst prognosis with about 
three quarters developing ESRD or dying following 
the presenting episode or as a consequence of 
relapse. In addition, the rates of relapse and post 
transplant recurrence are high9-13. Moreover, our 
patient’s family background with the early death of 
the affected parent makes us concerned that there 
may be an adverse future clinical course. Conse-
quently, determination of the best therapeutic strat-
egy is challenging.
Plasma therapy, including plasma infusion (PI) or 
plasma exchange (PEX), is considered the first-line 
therapy for aHUS and the recommended approach 
to treat both acute episodes and prevent recurrences, 
although conclusive evidence is still lacking13. In our 
patient, PI was started early together with conserva-
tive treatment (fluid and electrolyte management, 
transfusion and antihypertensive treatment)14,15. 
Since our patient had a functional CFH deficiency 
(demonstrated by a normal CFH level), PI with FFP 
was successful in replacing the mutant CFH comple-
ment regulator with functional proteins. To date, the 
child has shown a good response to treatment: with 
plasma therapy, both platelet count and serum LDH 
concentration (the most sensitive markers for moni-
toring response) improved steadily. Treatment fre-
quency and duration was tailored according to the 
individual patient response. If disease relapses, PEX 
will be an alternative treatment option in this child. 
Nevertheless, patients with CFH mutation-associated 
aHUS often progress to ESRD despite plasma therapy 
because of failure to respond and/or recurrent dis-
ease. So, it is expected that this child will need new 
treatment options for long-term management. When 
such patients are transplanted, aHUS almost invari-
ably recurs and causes graft failure making the ratio-
nale for renal transplantation questionable16.
New therapeutic options are being tested for 
aHUS, such as complement inhibition. In particular, 
blockade of the complement cascade at the level 
of C5 by eculizumab, a human anti-C5 monoclonal 
antibody has induced remission of acute episodes 
of aHUS refractory to plasma therapy and pre-
vented relapses after transplantation. However, 
adequate experience is lacking and an ongoing 
clinical trial is investigating the role of eculizumab 
therapy in the treatment of children with aHUS 
due to complement dysregulation17-19. Because it 
is known that CFH is synthesised by the liver, 
combined liver-kidney transplantation could also 
be an option but there are currently insufficient 
data to recommend this practice20.
In conclusion, this case report highlights the most 
recent advances in aHUS in children, in particular the 
advantage of genetic diagnosis. Prognosis is usually 
poor and careful long-term follow-up is required. 
Novel treatment options are now under development 
which may improve patient outcomes.
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